首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   539篇
  免费   45篇
  国内免费   9篇
  2022年   11篇
  2021年   14篇
  2020年   5篇
  2019年   8篇
  2018年   11篇
  2017年   8篇
  2016年   13篇
  2015年   15篇
  2014年   15篇
  2013年   18篇
  2012年   39篇
  2011年   22篇
  2010年   19篇
  2009年   25篇
  2008年   24篇
  2007年   19篇
  2006年   24篇
  2005年   9篇
  2004年   8篇
  2003年   5篇
  2002年   3篇
  2001年   6篇
  2000年   3篇
  1999年   13篇
  1998年   7篇
  1997年   6篇
  1996年   12篇
  1995年   3篇
  1994年   4篇
  1991年   3篇
  1989年   3篇
  1983年   4篇
  1980年   3篇
  1978年   5篇
  1977年   2篇
  1974年   3篇
  1972年   2篇
  1959年   7篇
  1958年   23篇
  1957年   26篇
  1956年   26篇
  1955年   22篇
  1954年   22篇
  1953年   13篇
  1952年   13篇
  1951年   10篇
  1950年   9篇
  1949年   2篇
  1948年   2篇
  1912年   2篇
排序方式: 共有593条查询结果,搜索用时 31 毫秒
81.
82.
The relationship between nucleolar and mitotic cycles has beendetermined after treatment of root apices of Zea mays with ethidiumbromide. In the meristematic regions of the stele the two cyclesare not much displaced in relation to each other except fora delay in the onset of the disorganization phase. A few nucleolipersist into metaphase and a few nuclei undergo an amitoticdivision. In the cap initials the drug greatly delays the onsetof disorganization of the nucleolus, which normally occurs beforeprophase in this region. It also delays the completion of reorganizationso that fully organized nucleoli are no longer available duringthe last half of telophase. In the quiescent centre the onsetof disorganization and the end of reorganization of the nucleoliare also delayed in relation to mitosis. There is no evidencefor a delay in the onset of reorganization in any region ofthe meristem. Some cells form multiple micronucleoli and this aberrant behaviouroccurs more often in the cap initials than elsewhere as doesamitotic division.  相似文献   
83.
84.
85.
In the Kingdom of Saudi Arabia (KSA), breast cancer constitutes 18% of all cancers in Saudi women. Whilst locally advanced breast cancer disease is unusual in Western countries, it constitutes more than 40% of all non-metastatic breast cancer in KSA. The relative frequency of locally advanced disease among our breast cancer population and the lack of a uniform consensus in the literature about its optimal management have prompted this retrospective analysis of the medical records of patients with Stage III breast cancer patients seen at King Faisal Specialist Hospital and Research Center between 1981 and 1991. In all, 315 patients were identified. Their median age ±SD was 46±11.6 years which is distinctly different from the 60–65 years median age in industrial Western nations. Most patients were younger than 50 years (64%) and premenopausal (62%). Patients were approximately equally divided between Stage III A and Stage III B Patients received multimodality treatment, including surgery., adjuvant chemotherapy, tamoxifen, and adjuvant radiotherapy. Sixty-one patients were excluded from survival analysis as they were considered lost to follow-up. Of the remaining 254 patients, 73 (29%) were alive and disease free, and 18 patients (7%) were alive but, with evidence of the disease. The remaining 163 (64%) had died from breast cancer or its related complications. Their median overall survival (OS) was 54 months, (95%, Cl, 27 to 121 months) and the median progression-free survival (PFS) was 28.8 months (95% Cl, 14.2 to 113 months). Cox proportional hazard, model identified Stage III B and the number of positive axillary lymph nodes as poor predictors of OS and PFS. Radiotherapy was the only adjuvant modality that affected survival favourably. The prognosis of patients with Stage III disease remains poor despite the use of a multimodality approach. The overall young age of our patients may have contributed to the poor outcome. Moreover, the adverse effect of Stage III B disease (as compared with Stage III A) and axillary nodal status was evident. Whilst the favourable effect of radiotherapy on survival was demonstrated, the lack of independent efficacy of other modalities (adjuvant chemotherapy and tamoxifen) or the apparent deleterious effect of neoadjuvant chemotherapy should be addressed with discretion in such retrospective analysis. Optimal management of patients with locally advanced breast cancer disease should be appraised in well designed, prospective, randomised studies.  相似文献   
86.
Individual plants of several Amelanchier taxa contain many polymorphic nucleotide sites in the internal transcribed spacers (ITS) of nuclear ribosomal DNA (nrDNA). This polymorphism is unusual because it is not recent in origin and thus has resisted homogenization by concerted evolution. Amelanchier ITS sequence polymorphism is hypothesized to be the result of gene flow between two major North American clades resolved by phylogenetic analysis of ITS sequences. Western North American species plus A. humilis and A. sanguinea of eastern North America form one clade (A), and the remaining eastern North American Amelanchier make up clade B. Five eastern North American taxa are polymorphic at many of the nucleotide sites where clades A and B have diverged and are thought to be of hybrid origin, with A. humilis or A. sanguinea as one parent and various members of clade B as the other parent. Morphological evidence suggests that A. humilis is one of the parents of one of the polymorphic taxa, a microspecies that we refer to informally as A. "erecta." Sequences of 21 cloned copies of the ITS1- 5.8S gene-ITS2 region from one A. "erecta" individual are identical to A. humilis sequence or to the clade B consensus sequence, or they are apparent recombinants of A. humilis and clade B ITS repeats. Amelanchier "erecta" and another polymorphic taxon are suspected to be relatively old because both grow several hundred kilometers beyond the range of one of their parents. ITS sequence polymorphisms have apparently persisted in these two taxa perhaps because of polyploidy and/or agamospermy (asexual seed production), which are prevalent in the genus.   相似文献   
87.
88.
89.
90.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号